The US (select pack) portfolio is expected to grow ~7% YoY to | 12808 crore due to 1) YoY strengthening of US$ vs. rupee (3.6%), 2) new launches (Dr Reddy's) and 3) increased traction/recovery in specialty, injectable portfolios (Albuterol Cipla, Lupin, Insulin Biocon, Injectables - Aurobindo). Domestic formulations (select pack) are expected to grow ~10% to | 9908 crore. Europe is expected to grow ~15% YoY driven by new launches, ramp-up in existing products and currency benefits. API segment is also expected to post strong ~16% YoY growth on the back of a low base effect and shortterm opportunities amid Covid. On the hospitals front, continued QoQ...